Dai Han Pharm Co Ltd

Dai Han Pharm maintains a strong liquidity position, with a current ratio of 3.64 and cash and equivalents amounting to KRW 43,957,795,930. The company's debt-to-equity ratio is 0.0, indicating no long-term debt obligations, which is a significant structural advantage compared to industry peers. Profitability metrics show a return on equity (ROE) of 9.21% and a return on assets (ROA) of 7.95%. These figures are in line with the industry's preferred metrics for profitability and suggest efficient use of equity and assets. The company's operating income of KRW 31,185,733,350 and net income of KRW 27,643,838,540 reflect strong earnings performance. The company operates through two segments: Manufacturing Pharmaceutical and Other Sales. The Manufacturing Pharmaceutical segment is the primary revenue driver, while the Other Sales segment contributes through test inspection services. Revenue concentration data is not explicitly provided, but the dual-segment structure suggests a balanced exposure to core pharmaceutical manufacturing and ancillary services. Dai Han Pharm's growth trajectory is supported by a robust revenue base of KRW 208,614,118,260 and a positive free cash flow of KRW 6,546,964,000. The company's capital expenditure of KRW -25,122,784,960 indicates a focus on cost management and operational efficiency rather than expansion. Analysts have assigned a mean recommendation of 1.50, indicating a generally positive outlook. Risk factors for Dai Han Pharm are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's low debt load and strong cash reserves mitigate financial risk. Additionally, the absence of dilution potential and the low risk score suggest a stable capital structure. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's consistent performance and lack of immediate risk factors suggest a stable and predictable business environment.